重症监护病房流感相关侵袭性曲霉病:一项前瞻性多中心队列研究
该研究在荷兰和比利时开展前瞻性多中心观察性队列,纳入2017–2020三个流感季节因呼吸窘迫入住ICU的成人PCR确诊流感患者及非流感社区获得性肺炎(niCAP)对照。侵袭性曲霉病在流感组发生率为24%(34/140),niCAP组为13%(10/76)(p=0.054)。IAPA患者ICU死亡率44%(15/34),显著高于单纯流感组的14%(15/106)和niCAP组的17%(13/76);IAPA是流感患者ICU死亡的独立预测因素(aHR 1.99,95%CI 1.05–3.76)。作者结论认为IAPA是危重流感患者的常见并发症,与高死亡率和不良临床过程相关,临床医生必须提高认识。
要点
- ICU流感患者中侵袭性曲霉病发生率为24%(34/140),中位诊断时间为入ICU后4天。
- IAPA患者ICU死亡率44%(15/34),显著高于单纯流感14%(15/106)和niCAP 17%(13/76)。
- IAPA是流感患者ICU死亡的独立预测因素(aHR 1.99,95%CI 1.05–3.76,p=0.035)。
- IAPA患者更常需要有创通气(90% vs 57%,p=0.001)和肾脏替代治疗(45% vs 13%,p<0.001)。
- IAPA死亡者中男性比例更高(87% vs 47%,p=0.030),ICU接受全身糖皮质激素者更多(93% vs 53%,p=0.020)。
适用人群与场景
- 纳入标准:2017–2020三个流感季节在荷兰和比利时ICU因呼吸窘迫住院的成人患者,PCR确诊流感或非流感社区获得性肺炎(niCAP,对照组)。
- niCAP诊断及真菌学检查由主治医师酌情决定。
诊断标准与关键阈值
- IAPA定义依据2020年专家意见病例定义。
研究设计与关键结果
- 研究类型:前瞻性、多中心观察性队列研究,在荷兰和比利时开展,历时三个流感季节(2017–2020)。
- 样本量:流感组140例,niCAP组76例。
- 主要结果:侵袭性曲霉病在流感组发生率为24%(34/140),niCAP组为13%(10/76)(p=0.054)。
- IAPA中位诊断时间:入ICU后4天。
- IAPA患者与单纯流感患者EORTC/MSGERC宿主因素无差异:9/32(28%)vs 22/85(26%),p=0.82。
- IAPA患者更常需要有创通气:26/29(90%)vs 50/88(57%),p=0.001;更常需要肾脏替代治疗:15/33(45%)vs 13/103(13%),p<0.001。
- ICU死亡率:IAPA组44%(15/34)vs 单纯流感组14%(15/106),p<0.001;niCAP组17%(13/76)。
- IAPA死亡者中男性比例更高:13/15(87%)vs 存活者9/19(47%),p=0.030;ICU接受全身糖皮质激素者更多:14/15(93%)vs 存活者10/19(53%),p=0.020。
证据类型、等级与局限
- 证据类型:前瞻性、多中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,IAPA是危重流感患者的常见并发症,与高死亡率和不良临床过程相关,临床医生必须提高认识。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Influenza-associated pulmonary aspergillosis (IAPA) can develop in critically ill patients with influenza in the intensive care unit (ICU), even in absence of classical risk factors. Thus far, most studies have been retrospective and the reported incidence has varied. Therefore, we set out to prospectively investigate IAPA incidence, potential risk factors and impact on patient outcomes. METHODS: A prospective, multicentre observational cohort study was performed in the Netherlands and Belgium during three influenza seasons (2017–2020). Adult patients with PCR confirmed influenza or non-influenza community-acquired pneumonia (niCAP; control group) admitted to ICU with respiratory distress were included. Diagnosis of niCAP and mycological diagnostic work-up was at the treating physicians’ discretion. IAPA was defined according to the 2020 expert opinion case definition. RESULTS: Invasive aspergillosis occurred in 24% (34/140) of patients with influenza, compared to 13% (10/76) of patients with niCAP (p = 0.054) undergoing mycological diagnostic work-up and radiological imaging. IAPA was diagnosed at a median of 4 days after ICU admission. Patients with IAPA did not differ from those with influenza alone regarding presence of European Organization for Research and Treatment of Cancer/Mycosis Study Group Education and Research Consortium (EORTC/MSGERC) host factors (9/32 [28%] versus 22/85 [26%], respectively; p = 0.82). They more frequently required invasive ventilatory support (26/29 [90%] versus 50/88 [57%], respectively; p = 0.001) and renal replacement therapy (15/33 [45%] versus 13/103 [13%], respectively; p < 0.001) in ICU. IAPA ICU mortality was significantly higher with 44% (15/34) compared to 14% (15/106) for influenza without aspergillosis (p < 0.001) and 17% (13/76) for niCAP. Non-survivors with IAPA were predominantly male (13/15 [87%] versus 9/19 [47%] survivors; p = 0.030) and more frequently received systemic corticosteroids in ICU (14/15 [93%] versus 10/19 [53%] survivors; p = 0.020). IAPA was an independent predictor of ICU mortality in patients with influenza (adjusted hazard ratio 1.99 [95% confidence interval 1.05 – 3.76]; p = 0.035). CONCLUSIONS: We demonstrate prospectively that IAPA is a frequent complication in critically ill patients with influenza and that it is associated with high mortality and an adverse clinical course, rendering increased awareness among treating physicians imperative.
参考来源
- Janssen NAF, Vanderbeke L, Jacobs C, et al. Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study. Crit Care. 2025. PMID: 41318517. doi:10.1186/s13054-025-05771-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。